No Evidence for Trump’s Right to Try Claim

As helium has done for years, President Donald Trump claims – without grounds – that the national Right to Try instrumentality helium signed successful 2018 has “saved thousands of lives.” But the White House provided nary enactment for Trump’s assertion astir the law, which provides an alternate way for earnestly sick patients to entree unapproved drugs extracurricular of objective trials. 

Researchers who person agelong studied entree to investigational drugs accidental the president is greatly exaggerating.

“It’s not that cipher is utilizing Right to Try. There person been a fistful of reported cases,” Holly Fernandez Lynch, subordinate prof of aesculapian morals astatine the University of Pennsylvania Perelman School of Medicine, told america successful an interview. “But surely it has not been thousands of patients … who’ve received cause therapy, fto unsocial had their lives saved by these products.”

Alison Bateman-House, co-chair of NYU Grossman School of Medicine’s Working Group connected Compassionate Use & Preapproval Access, said successful an interrogation that Trump’s assertion astir the instrumentality redeeming thousands of lives is simply a “gross misestimate.”

Dr. Jeffrey A. Singer, a elder chap astatine the libertarian Cato Institute who said helium supported transition of the 2018 national law, present says that it “fail[ed].” In a May opinion piece for Reason magazine, Singer argues for changes to the Right to Try law, penning that the committedness of a close to effort imaginable life-saving drugs “often exists much connected insubstantial than successful practice.”

Reason, May 12: The income transportation was sweeping. When President Donald Trump signed Right to Try successful 2018, surrounded by patients, helium promised a “fundamental freedom” that would springiness dying patients hope.

Eight years later, the grounds is acold thinner than the rhetoric. The [Food and Drug Administration] reports lone a fistful of uses each year—12 drugs from 2018 to 2022, and conscionable a fewer much annually since. It wasn’t a caller pathway truthful overmuch arsenic a support gaffe that seldom translates into access.

The FDA is required to publically study the fig of investigational drugs utilized nether the Right to Try instrumentality – but not however galore patients person been treated. FDA yearly summaries amusement that 21 investigational drugs person been utilized from May 30, 2018, done Dec. 31, 2024.

The FDA did not respond to our petition for the fig of patients treated nether the national law. 

We asked the White House for the fig of patients treated nether the Right to Try instrumentality and grounds that thousands of lives were saved. But it provided nary enactment for Trump’s assertion — which helium repeated throughout the 2024 statesmanlike campaign, including successful his acceptance code astatine the 2024 Republican convention. Most recently, the president said in April that Right to Try has “saved thousands and thousands of lives,” and helium said it again in May, erstwhile helium claimed the instrumentality has “saved thousands of lives,” but “nobody talks astir it.”

“President Trump is right: Right to Try was a historical triumph from his archetypal term, which has allowed galore Americans to entree treatments that would person different been blocked by the regulatory support process,” White House spokesperson Kush Desai said successful an email.

The Goldwater Institute, which takes recognition for helping to enact 41 authorities Right to Try laws anterior to transition of the national law, provides immoderate examples connected its website of patients utilizing Right to Try laws connected the state and federal level. But the institute – which claims the “Right to Try instrumentality has a proven way record” – doesn’t cognize however galore patients person received investigational drugs done the national law.

“[U]nfortunately the Goldwater Institute is not capable to way utilization of Right to Try fixed diligent privateness laws,” Goldwater Institute spokesperson Ryan Mills told america successful an email.

Right to Try and the FDA

The national Right to Try instrumentality was arguable from inception due to the fact that it removes the FDA from the oversight and support process for the usage of unapproved drugs extracurricular of objective trials. Under Right to Try, unapproved drugs tin beryllium utilized without FDA support to dainty patients diagnosed with a “terminal illness,” which is defined arsenic a “life-threatening illness oregon condition,” who person exhausted approved options and are incapable to enactment successful a objective trial.

Critics accidental Right to Try is unnecessary – and perchance unsafe – due to the fact that the FDA has agelong had an expanded entree program that allows patients to usage unapproved drugs extracurricular of objective trials.

In 2016, erstwhile a Senate committee was considering Right to Try legislation, then-FDA authoritative Peter Lurie credited the expanded entree programme for making unapproved drugs disposable rapidly to thousands of earnestly sick patients, portion protecting “desperate patients” from “unnecessary risks” and exploitation by “unscrupulous individuals.”

“FDA has authorized much than 99 percent (7110/7176) of azygous diligent expanded entree Investigational New Drug (IND) requests received successful Fiscal Years 2010-2015. Emergency requests are usually granted instantly implicit the telephone and non-emergencies are processed successful a median of 4 days,” Lurie, who was subordinate FDA commissioner for Public Health Strategy and Analysis, said successful written testimony. 

Since then, the fig of requests has accrued and support rates person remained mostly unchanged.

For fiscal years 2019 done 2023, the FDA approved 99% (17,806/17,964) of single-patient expanded entree IND requests, the most caller FDA data show. Several experts connected FDA instrumentality and argumentation told america that these figures suggest that Right to Try hasn’t had overmuch of an impact.

“If you look astatine the accusation FDA publishes astir expanded entree requests, you spot that FDA authorizes the overwhelming bulk of them. You know, galore years, 99%,” Patricia Zettler, a instrumentality prof astatine Ohio State University who teaches nationalist wellness and FDA instrumentality courses, told america successful an interview. “Given that, there’s … nary logical crushed to deliberation Right to Try would alteration the scenery dramatically.” (Zettler served arsenic lawman wide counsel astatine the Department of Health and Human Services, covering the FDA, during the Biden administration.)

Under some pathways – Right to Try and the expanded entree programme – companies processing caller drugs are not required to marque them disposable to patients. As a result, pharmaceutical companies — not the FDA — stay “the larger obstacle” to giving patients entree to unapproved drugs, Lurie told america successful an interview.

“Companies are much apt to accidental nary than the FDA, by far,” Lurie said. “The assertion that FDA is the obstacle is not true.” 

Bateman-House told america that “large biopharmaceutical companies are not utilizing Right to Try … due to the fact that if you’re trying to bring a merchandise to marketplace done the FDA, you don’t truly person immoderate inducement to debar the FDA erstwhile you’re handing retired your unapproved product.”

One inducement for biopharmaceutical companies to question FDA oversight, she said, is that the bureau tin gully upon confidential proprietary accusation it has from objective trials and different expanded entree treatments to necessitate companies to alteration projected attraction plans anterior to approving expanded entree requests. That protects diligent information and benefits the improvement of the investigational drug, Bateman-House said.

Pfizer and Johnson & Johnson, for example, person said that they enactment FDA oversight erstwhile providing investigational drugs extracurricular of objective trials. 

In 2015, Johnson & Johnson created a bioethics sheet headed by Arthur Caplan, co-chair of NYU Grossman School of Medicine’s Working Group connected Compassionate Use & Preapproval Access, to make a argumentation connected the usage of investigational drugs. In its policy statement, Johnson & Johnson said FDA oversight is required “to guarantee afloat information of disposable information information of which the FDA whitethorn beryllium uniquely aware.”

In an article past twelvemonth for the American Health Law Association, Barbara Bierer, a prof astatine Harvard Medical School, and her co-authors wrote that physicians are besides reluctant to usage Right to Try, successful portion due to the fact that of “the abrogation of regulatory and ethical oversight.”

The article, which said “data connected the prevalence of RTT are scant,” cited a survey of assemblage oncologists that recovered 46% of 238 respondents attempted to usage the expanded entree program, portion lone 14% of the respondents attempted to usage Right to Try. The insubstantial besides cited the American Society of Clinical Oncology’s opposition to Right to Try.

American Health Law Association, Jan. 24, 2025: Current information connected the prevalence of RTT are scant, but the information that are disposable suggest that oncologists are considerably much apt to petition entree to an unapproved cause via EAP than they are via RTT. Given that the large quality betwixt EAP and RTT is FDA oversight, a threshold question is whether FDA acts to deter oregon hold the support of EAP requests. Evidence suggests that arsenic galore arsenic 99% of each EAP requests are approved by FDA often wrong the archetypal fewer days.

Despite its societal media beingness and visibility, request for entree via RTT has yet to materialize. Some experts person explicitly advised physicians to “steer patients distant from RTT and toward [EAP]” portion others assertion they would ne'er promote a diligent to avail themselves of RTT. The American Society of Clinical Oncology (ASCO) released a nationalist connection condemning RTT, stating “ASCO supports entree to investigational drugs extracurricular of objective trials erstwhile capable diligent protections are successful spot . . . We don’t enactment close to effort legislation, however, due to the fact that these laws disregard cardinal diligent protections without really improving diligent entree to investigational drugs extracurricular of objective trials.”

One happening that critics and supporters of the Right to Try tin hold connected is that the propulsion for specified laws connected the authorities and national level has raised consciousness of the FDA’s expanded entree program.

“The astir charitable happening I tin accidental is, I deliberation the Right to Try instrumentality astir apt accrued consciousness of the thought that it is imaginable to usage unapproved drugs extracurricular of objective trials,” Bateman-House told us. “Maybe immoderate fig of radical were capable to acquisition a affirmative wellness payment via that. But it wasn’t due to the fact that of Right to Try. It was due to the fact that they were asking for thing that they had had entree to each along. They conscionable didn’t recognize they had access.”

Singer, the Cato elder fellow, independently raised the aforesaid constituent successful a abstracted interrogation with us.

Singer — who was a visiting chap astatine the Goldwater Institute from 2017 to 2026 — told america that helium inactive supports the “concept” of Right to Try, adjacent though helium believes “there haven’t been galore instances of Right to Try” being utilized to marque unapproved drugs disposable to earnestly sick patients.

He added that helium did not privation to minimize the indirect benefits of the law. Singer said Right to Try had “an interaction connected the FDA” by raising nationalist consciousness of the expanded entree programme and forcing the bureau to simplify its expanded entree exertion process.

Singer sent america a nexus to the same survey of oncologists cited by the American Health Law Association. That insubstantial said “awareness of the EA programme was precocious among the assemblage oncologists we surveyed.” It besides said the “revised, simplified” expanded entree exertion present takes lone 45 minutes to capable out.

As we mentioned, determination has been an summation successful expanded entree requests and approvals, truthful determination is information to enactment the mentation that the Right to Try instrumentality has had an indirect benefit. But determination is nary grounds to enactment the president’s assertion that the instrumentality has “saved thousands of lives.”

---

Editor’s note: FactCheck.org does not judge advertising. We trust connected grants and idiosyncratic donations from radical similar you. Please see a donation. Credit paper donations whitethorn beryllium made through our “Donate” page. If you similar to springiness by check, nonstop to: FactCheck.org, Annenberg Public Policy Center, P.O. Box 58100, Philadelphia, PA 19102. 

The station No Evidence for Trump’s Right to Try Claim appeared archetypal connected FactCheck.org.